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Effect of insulin-plus-glucose infusion with and without epinephrine on
fasting hyperkalemia. Extrarenal potassium disposal is an important
defense against hyperkalemia in patients with end-stage renal disease.
both insulin and epinephnne are important modulators of this process.
Hemodialysis patients are prone to developing hyperkalemia during
fasting. We tested the hypothesis that the infusion of physiologic doses
of insulin prevents fasting hyperkalemia in hemodialysis patients, both
by a direct stimulation of extrarenal potassium disposal, as well as by
augmenting the potassium-lowering effect of epinephrine. Ten stable,
nondiabetic maintenance hemodialysis patients were studied prospec-
tively in a Clinical Research Center. They were fasted for 18 hours,
followed by an acute infusion of epinephrine at 0.01 gfkg/min, in the
absence or presence of prior beta-blockade with propranolol. Serial
measurements of plasma potassium, insulin and glucose were obtained.
The patients were restudied under the same experimental protocols,
while receiving a continuous infusion of insulin with dextrose. The
plasma potassium increased by 0.58 0.13 mmol/liter (P = 0.002) after
18 hours of fasting. Administration of insulin with dextrose at a dose
that doubled the plasma insulin levels within the physiologic range (9.3
1.1 vs. 20.2 2.3 mU/liter, P < 0.002), completely prevented the rise
in plasma potassium (+0.06 0.13 mmollliter, P = 0.64). Epinephrine
did not significantly change the plasma potassium during fasting alone
(+0.05 0.09mmol/liter, P 0.59), whereas it lowered the potassium
significantly (—0.16 004 mmol/liter, P = 0.003) when the subjects
were receiving insulin with glucose. Epinephrine in the presence of
beta-blockade produced similar increases in plasma potassium in the
absence or presence of concomitant administration of insulin with
glucose (0.25 0.10 vs. 0.20 0.03 mmol/liter). These observations
demonstrate that insulin-with-glucose at physiologic doses prevents
fasting hyperkalemia in hemodialysis patients, both by directly stimu-
lating uptake of potassium into the cells, as well as by potentiating the
potassium-lowering effect of beta-adrenergic stimulation. We propose
that when hemodialysis patients prone to hyperkalemia are fasted in
preparation for surgery or a diagnostic procedure, a continuous infusion
of insulin with dextrose may prevent hyperkalemia.
Patients with end-stage renal disease are susceptible to de-
veloping hyperkalemia, since their renal excretion of potassium
is negligible. Whereas a progressive rise in plasma potassium
during the interdialytic period in fed hemodialysis patients is
well recognized, the rise in plasma potassium when these
patients are fasted has only recently been reported [1]. Extra-
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renal potassium disposal, by shifting potassium from the extra-
cellular to the intracellular fluid compartment, assumes partic-
ular importance in the defense against hyperkalemia in patients
with end-stage renal disease. The two major physiologic stimuli
for extrarenal disposal of potassium are insulin and catechola-
mines [2]. It has long been recognized that the administration of
pharmacologic doses of insulin can acutely lower the serum
potassium concentration in normal individuals [3, 4]. This effect
of insulin is preserved in patients with renal failure [5], and is
frequently used for the rapid treatment of severe hyperkalemia
in patients with renal failure [6—8]. It is not clear, however,
whether small doses of exogenous insulin, so as to raise plasma
insulin concentrations within the physiologic range, can prevent
fasting hyperkalemia in hemodialysis patients.
Epinephrine at physiologic doses acutely lowers the plasma
potassium concentration in normal subjects, an effect that is
mediated by beta-2 receptors [9—11]. Selective beta-2 agonists,
such as albuterol, lower the plasma potassium in both normal
subjects [12, 13] and in patients with end-stage renal disease [6,
8, 14, 151. In contrast, the potassium-lowering effect of epineph-
rifle is blunted in hemodialysis patients [1, 16—18]. Since epi-
nephrine is a mixed alpha- and beta-agonist, the net effect of
infused epinephrine on plasma potassium depends on the rela-
tive balance between its alpha (potassium-raising) and beta-2
(potassium-lowering) agonist effects. A recent study reported
that epinephrine infusion during beta-blockade with propranolol
produced a significantly greater increase in plasma potassium in
dialysis patients, as compared to normal controls. This obser-
vation suggests that the resistance to the hypokalemic effect of
epinephrine in hemodialysis patients was due to an enhanced
alpha-adrenergic effect [16]. It is not known whether physio-
logic concentrations of insulin can overcome the resistance to
the hypokalemic effect of epinephrine in dialysis patients.
The present study was designed to evaluate the effect of
exogenous insulin in physiologic doses on extrarenal potassium
disposal in fasting hemodialysis patients. Specifically, the goals
were: (1) to determine whether administration of insulin in
physiologic doses prevents the rise in plasma potassium during
fasting in dialysis patients; (2) to determine whether physiologic
doses of insulin can overcome the resistance to the potassium-
lowering effect of epinephrine in fasted hemodialysis patients;
and (3) to determine whether exogenous insulin affects the
alpha- or beta-adrenergic component of the epinephrine action.
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Methods
Subjects
Ten nondiabetic chronic hemodialysis patients were recruited
from the outpatient dialysis units at the University of Alabama
at Birmingham and the Veterans Administration Medical Cen-
ter in Birmingham, Alabama. Each patient had been undergoing
maintenance dialysis three times per week, for 3.5 to 4 hours on
each occasion, for at least three months. Exclusion criteria for
the subjects included: presence of congestive heart failure,
angina, or an unstable heart rhythm [more than 3 premature
ventricular contractions (PVC'S) per minute or multifocal or
complex PVC's]; hematocrit below 0.25; medication with digi-
talis, beta-blockers, or alpha-blockers during the seven days
prior to the study. The study population included six men and
four women, with ages ranging between 29 and 64 (mean SD,
49 11 years). Each subject provided informed, written
consent for participation in the experimental protocol which
had been approved by the University of Alabama at Birming-
ham Institutional Review Board.
Experimental protocols
Protocol 1. All experiments were performed on an inpatient
basis in the General Clinical Research Center (GCRC). The
study design was a prospective, crossover trial in which each
subject acted as his or her own control. Each subject was
studied on two separate occasions separated by at least one
week. On each occasion, the subject was admitted to the GCRC
in the early afternoon, following his or her usual dialysis
schedule, which ended by 10a.m. earlier that day, The timing of
the study relative to the last dialysis treatment was designed to
start at a relatively normal plasma potassium concentration, to
minimize the risk of severe hyperkalemia [1]. On the first study
session, an 18 hour fast was initiated following a standardized
dinner at 5 p.m. An indwelling venous catheter was placed in
the dialysis graft for repeated blood collections, and maintained
patent with heparin flushes. Blood samples and measurements
of vital signs were obtained at 11 p.m., 5a.m., 8a.m., and 11
a.m. (after 6, 12, 15, and 18 hours of fasting). Then, a continu-
ous infusion of epinephrine, 0.01 tg/kg/min, was infused over
one hour. During this infusion, continuous electrocardiographic
monitoring was done. Blood samples and vital signs were
obtained at 15 minute intervals. The following criteria were
prospectively chosen to prematurely terminate the epinephrine
infusion: (1) rise of systolic blood pressure to >200 or diastolic
blood pressure to >120 mm Hg; (2) heart rate >120 min; (3)
ventricular arrhythmias (more than 3 PVC's per minute or
multifocal or complex PVC's); (4) development of angina. None
of the subjects developed any of these criteria.
The second study session followed the identical research
protocol, except that an infusion of 10% dextrose, with 20 units
of regular insulin added to each liter, was given in the contralat-
eral arm at 50 ml/hr, from the beginning of the fast to the end of
the experiment.
Protocol 2. To evaluate whether exogenous insulin was
interacting with the alpha- or beta-adrenergic component of
epinephrine, six of the subjects were restudied on two addi-
tional occasions. After an 18 hour fast, they received a 30
minute infusion of propranolol at 1.43 gIkg/min, followed by a
45-minute infusion of epinephrine at 0.01 p.g/kg/min. This
experimental protocol has been previously shown to provide a
valid measure of the alpha-adrenergic component of the effect
of epinephrine on plasma potassium [16]. Each subject was
studied under the identical protocol in the absence and in the
presence of a continuous infusion of insulin with dextrose, as
described in protocol 1. Monitoring of cardiac rhythm and vital
signs was carried out as described in protocol 1.
Protocol 3. Because the infusion of exogenous glucose can
stimulate endogenous insulin secretion, further studies were
performed to evaluate whether an infusion of glucose alone
(without insulin) would also prevent fasting hyperkalemia in
hemodialysis patients. We re-studied the three patients from
protocol 1 who had developed the greatest increase in plasma
potassium during the 18 hour fast. During the repeat study these
subjects received an infusion of 10% dextrose (without insulin)
at 50 ml/hr, and several blood samples were collected during the
18 hour fast.
Biochemical analysis
All blood samples were collected in heparinized tubes, spun
promptly, and the plasma assayed for potassium, glucose,
bicarbonate, and insulin. Potassium was measured by a flame
photometer. Plasma glucose and bicarbonate was measured by
automated biochemical methods (Kodak Ektachem 700XR).
The remaining samples were frozen for subsequent determina-
tions of insulin concentrations by radioimmunoassay.
Statistical analysis
Since the subjects were fed at 5 p.m. (time 0), all values
measured between 12 to 18 hours of fasting were compared to
the six-hour postprandial values. This was done to minimize the
effect of the dietary potassium provided with the dinner. The
effects of fasting and epinephrine infusion on various biochem-
ical parameters was evaluated using the NCSS statistical soft-
ware. Comparisons between treatment protocols in which sub-
jects did or did not receive insulin with dextrose were
performed by paired Student t-tests. Changes within a given
experiment were analyzed by analysis of variance (ANOVA)
for repeated measures. A P value less than 0.05 was considered
statistically significant.
Results
Observations during the 18 hour fast
The plasma potassium concentration prior to the dinner
preceding the fast was 3.95 0.24 mmollliter. Six hours after
initiation of the fast, the plasma potassium concentration was
not different in the absence or presence of exogenous infusion
of insulin with dextrose (3.88 0.18 vs. 3.87 0.24 mmollliter).
During the subsequent twelve hours of fasting in the absence of
insulin administration, there was a progressive increase in
plasma potassium, averaging 0.58 0.13 inmol/liter (Fig. 1). In
one patient the plasma potassium increased by 1.2 mmol/liter.
The increase in potassium was completely abolished when an
infusion of insulin with dextrose was provided during the fast
(maximal increase, 0.06 0.13 mmol/liter). The insulin infusion
resulted in a doubling of plasma insulin levels within the
physiologic range (Fig. 1).
The plasma glucose concentrations were lower when the
subjects received an insulin infusion than when they were
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A Table 1. Plasma glucose and bicarbonate concentrations during an 18
4 8 hour fast in hemodialysis patients
---I - I
0 6 12 18
fasted without insulin administration (Table 1). One of the
patients developed symptomatic hypoglycemia (plasma glucose
of 1.7 mmollliter) 12 hours after starting the infusion, which
resolved after the administration of an intravenous bolus of
dextrose. The plasma bicarbonate concentration tended to
decrease slightly during the 18 hour fast with both experimental
protocols. However, at each time point, it was similar during
the fast alone or fast with insulin infusion (Table 1).
In the subjects who were re-studied under protocol 3 (infu-
sion of glucose without insulin), the rise in potassium during the
18 hour fast was intermediate between that observed in the
absence of an exogenous infusion and that observed during the
infusion of insulin with glucose (Table 2). Similarly, the plasma
insulin at the end of the 18 hour fast was intermediate between






6 hours 5.3 0.3 4.6 0.3c
12 hours 4.9 0.1 3.5
15 hours 4.8 0.2 3.6 0.3
18 hours 4.7 0,2b 3 3b,d
Plasma bicarbonate mmol/liter
6 hours 25.3 0.5 25.7 0.6
12 hours 24,6 0.6 24.8 0.4
15 hours 24.2 0.7 24.0 0.5'







6 hours 4.5 0.3 4.7 0.2 4.3 0.2
12 hours 5.0 0.2 4.5 0.4 4.6 0.3
15 hours 5.1 0.1 4.6 0.5 4.6 0.3
18 hours 5.4 0.1 4.7 0.5 4.8 0.3
Maximal change 0.9 0.2k 0.0 0.3 0.5 0.2
Plasma glucose mmol/liter
6 hours 5.4 0.9 4.7 0.5 5.9 0.1
12 hours 4.7 0.1 3.5 0.4 5.5 0.2
15 hours 4.2 0.4 3.5 0.2 5.1 0.1
18 hours 4.4 0.5 3.9 0.3 5.0 0.1
Plasma insulin ,nU/liter
6 hours 23.2 15.6 28.4 8.1 22.8 3.0
12 hours 9.2 3.2 23.8 5.5 11.5 2.8
15 hours 9.2 2.8 21.2 4.2 11.4 2.0
18 hours 9.0 2.6 23.0 6.4 9.9 2.9
Observations during the epinephrine infusion (protocol 1)
The one hour infusion of epinephrine during the last hour of
fasting did not produce a significant change in plasma potassium
concentration, in the absence of exogenous insulin (Fig. 2). In
contrast, when the subjects were infused with insulin, concur-
rent epinephrine administration resulted in a significant de-
crease in plasma potassium.
The plasma glucose concentration increased slightly, but
significantly, during the epinephrine infusion in the first proto-
col (Table 3). In contrast, there was no significant change when
the epinephrine infusion was superimposed on the insulin
infusion. The epinephrine infusion did not significantly change
the plasma insulin concentration, either in the absence or






























Values represent means SE for 10 subjects.
______
a p < 0.05, b P < 0.01 vs. the value at 6 hours
P < 0.05, ' P < 0.01 vs. the corresponding value in the protocol0 without insulin replacement
Table 2. Comparison of effects of no infusion, insulin-plus-glucose,
or glucose alone on plasma potassium, glucose, and insulin during an
18-hour fast in hemodialysis patients
Hours of fasting
Fig. 1. Serial plasma potassium and insulin concentrations during an
18 hour fast in hemodialysis patients in the absence (solid squares) or
presence (open squares) of a continuous physiologic infusion of insulin
with dextrose. Values represent means SE for 10 patients. * P < 0.05,
** P < 0.01 vs. the value at 6 hours of fasting; + P < 0.01 vs. the
corresponding value in the control experiment.
Values represent means SE for the three subjects with the greatest
increase in plasma potassium during the fast.
a P < 0.02










Fig. 3. Effect of epinephrine infusion (0.01 p.g/kg/min) during beta-
blockade with propranolol on plasma potassium in fasted dialysis
patients in the absence (solid squares) or presence (open squares) of a
continuous physiologic infusion of insulin with dextrose. Values repre-
sent means + SE for 6 patients. Baseline values are those measured at
the end of an 18 hour fast (see Fig. 1).
Table 4. Plasma glucose and insulin concentrations during the







Baseline 5.2 0.2 3.9 0.4
15 mm 5.7 0.4k 4.2 0.5
30 mm 5.8 0.3a 43 0.6
45 mm 5.9 Ø4 4.2 0.6
Insulin mU/liter
Baseline 9.9 1.6 19.0 2.1
15 mm 7.0 1.1 22.3 1.4
30 mm 8.3 1.8 20.8 2.4
45 mm 10.6 2.5 22.4 3.6
Values represent means SE for 6 subjects. Baseline values are those
measured after an 18 hour fast.
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Fig. 2. Effect of epinephrine infusion (0.01 ,g/kg/min) on plasma
potassium in fasted dialysis patients in the absence (solid squares) or
presence (open squares) of a continuous physiologic infusion of insulin
with dextrose. Values represent means + SE for 10 patients. Baseline
values are those measured at the end of an 18 hour fast (see Fig. I).
Table 3. Plasma glucose and insulin concentrations during the
epinephrine infusion in fasting hemodialysis patients






Baseline 4.5 0.1 3.9 0.3
15 mm 4.7 0.l 3.6 0.3
30 mm 4.8 0.la 3.9 0.3
45 mm 4.8 0.2a 3.9 0.3
60 mm 4.8 0.2a 4.2 0.3
Insulin m U/liter
Baseline 7.9 0.9 21.6 2.1
15 mm 8.6 1.2 19.6 1.7
30 mm 9.6 1.3 20.7 2.0
45 mm 9.9 1.2 19.6 1.8
60 mm 9.0 1.3 20.6 1.9
Values represent means SE for 10 subjects. Baseline values are
those measured after an 18 hour fast.
P < 0.01 vs. the baseline value
The patients' heart rate increased significantly during epi-
nephrine infusion in the absence of insulin administration (+ 5.2
1.4 min1 at 60 mm, P = 0.005) and in its presence (+2.9
1.2 min at 60 mm, P = 0.04).
Observations during the epinephrine infusion with beta-
blockade (protocol 2)
Infusion of epinephrine during beta-blockade with proprano-
lol produced a significant increase in plasma potassium concen-
tration. However, the magnitude of this increase was not
different in the absence or presence of exogenous insulin
administration (Fig. 3).
The plasma glucose concentration increased significantly
during epinephrine infusion superimposed on beta-blockade
(Table 4). This increase was prevented when the subjects were
receiving an exogenous insulin infusion. The epinephrine infu-
sion failed to significantly change the plasma insulin concentra-
tions either in the absence or presence of insulin administration.
In the presence of beta-blockade, epinephrine did not pro-
duce a significant change in heart rate, either in the absence or
presence of exogenous insulin (—0.4 1.6 and —1.0 0.7
min', respectively).
Discussion
The present study shows that an exogenous infusion of
insulin prevents fasting hyperkalemia in hemodialysis patients.
This effect was observed at doses of insulin that increased
plasma insulin concentrations within the physiologic range.
Moreover, physiologic doses of insulin had a permissive effect
in enhancing the potassium-lowering effect of epinephrine.
The failure of a physiologic dose of epinephrine to lower
plasma potassium in fasted hemodialysis patients is in agree-
ment with previous reports [1, 16—18]. The current investigation
suggests that physiologic doses of exogenous insulin can over-
come this resistance (Fig. 2). Alternatively, one might speculate
that plasma epinephrine levels might be higher in the patients
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who had been receiving prior infusion of insulin with glucose.
As a result these patients would develop higher epinephrine
levels during the epinephrine infusion, resulting in a decrease in
plasma potassium. Since plasma epinephrine levels were not
measured in the present study, this possibility cannot be
excluded. However, in a previous study plasma epinephrine
levels were not significantly different in normal fasting subjects
infused with epinephrine plus insulin with glucose, as compared
to the levels obtained during the infusion of epinephrine by
itself [191.
A potassium-lowering effect of beta-2 adrenergic stimulation
has been demonstrated in hemodialysis patients [6, 8, 14, 15]. A
recent study also provided evidence for an enhanced alpha-
adrenergic effect to raise plasma potassium in hemodialysis
patients [16]. Insulin could enhance the potassium-lowering
effect of epinephrine either by potentiating the beta-adrenergic
effect or by antagonizing the alpha-adrenergic effect. In the
present investigation, insulin had no effect on the magnitude of
the hyperkalemic effect of alpha-stimulation, as deduced from
the effect of epinephrine infusion following beta-blockade (Fig.
3). This suggests that the effect of insulin was to augment the
beta-adrenergic action of epinephrine. Such an interpretation of
the experimental results assumes that beta-blockade does not in
itself blunt the effect of insulin on extrarenal potassium dis-
posal. In fact, a previous human study reported that proprano-
lol did not modify the insulin-induced decrease in plasma
potassium in normal subjects, even though it attenuated the
decrease in plasma phosphate by 48% [20].
An additive effect of insulin at pharmacologic doses with the
beta-2 agonist, albuterol, has been previously reported in he-
modialysis patients [6]. The present study suggests that such an
interaction occurs even at physiologic concentrations of insulin.
This conclusion is in agreement with a number of in vitro
observations. Insulin and epinephrine have an additive effect in
promoting potassium uptake by isolated skeletal muscle [21].
Both epinephrine and insulin stimulate extrarenal potassium
disposal by enhancing the activity of the Na, K-ATPase [221.
The effect of epinephrine is mediated via cyclic AMP, whereas
the exact mechanism for the effect of insulin remains poorly
delineated. Some studies have suggested a stimulation by
insulin of the alpha-2 subunit of the Na, K-ATPase enzyme
[23, 24]. Recent reports have demonstrated in skeletal muscle
from uremic rats an impaired activity of the alpha- 1 subunit of
Na, K-ATPase, as well as an enhanced stimulation by insulin
of the pump activity [25, 26].
It has long been recognized that hemodialysis patients exhibit
a progressive increase in plasma potassium during the interdi-
alytic period, and this has been attributed to dietary intake of
potassium that cannot be excreted. More recently, Gifford et al
[1] have reported that hyperkalemia develops when hemodial-
ysis patients are fasted. The 0.58 mmol/liter increase in plasma
potassium observed during fasting in hemodialysis patients in
the present study is in close agreement with the 0.5 mmollliter
increase documented in the previous study [1]. In the absence
of renal excretion of potassium in functionally anephric pa-
tients, the rise in potassium during fasting is more likely due to
a net shift of potassium from the intracellular to the extracellu-
lar compartment. Exogenous insulin, by promoting potassium
influx into the cells, prevents fasting hyperkalemia in hemodi-
alysis patients.
Epinephrine acutely increased the plasma glucose concentra-
tion, in the absence of a change in plasma insulin, as has
previously been reported in hemodialysis patients [1, 16]. This
effect has been attributed to the stimulation of gluconeogenesis
by beta-adrenergic agonists [27]. In the presence of an infusion
of exogenous insulin, the hyperglycemic effect of epinephrine
was abolished. This effect may be attributable to the inhibition
of gluconeogenesis by insulin [28]. The persistence of the
increase in plasma glucose when epinephrine was given in the
presence of beta-blockade seems paradoxical. However, alpha-
adrenergic stimulation directly decreases insulin secretion by
the pancreatic beta-cells, which in turn decreases glucose
uptake by the tissues [29]. The infusion of exogenous insulin
prevented the hyperglycemic effect of epinephrine during beta-
blockade.
The results of the present study suggest that hyperkalemia
may be a clinically important problem when hemodialysis
patients are fasted, and that it can be avoided by the adminis-
tration of exogenous insulin. To minimize the risk of severe
hyperkalemia, we intentionally started the fast at a time when
the plasma potassium was relatively normal. It is likely that a
fast initiated at a later time relative to the last dialysis would
result in clinically significant hyperkalemia in some patients.
We propose that whenever hospitalized hemodialysis patients
prone to hyperkalemia are fasted in preparation for surgery or a
diagnostic procedure, they should receive an infusion of insulin
with dextrose. Exogenous glucose alone, by stimulating endo-
genous insulin secretion, may also be efficacious in attenuating
fasting hyperkalemia in hemodialysis patients, although our
data suggest that it is less efficacious than the infusion of insulin
with glucose (Table 2). Moreover, the protective effect of
exogenous glucose may be less predictable in chronic renal
failure, due to the impairment of pancreatic insulin secretion
[30]. Certainly, in diabetic dialysis patients, a combined infu-
sion of insulin with dextrose would be mandatory.
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